BRPI0409916A - ácidos carboxìlicos substituìdos com fenila - Google Patents

ácidos carboxìlicos substituìdos com fenila

Info

Publication number
BRPI0409916A
BRPI0409916A BRPI0409916-8A BRPI0409916A BRPI0409916A BR PI0409916 A BRPI0409916 A BR PI0409916A BR PI0409916 A BRPI0409916 A BR PI0409916A BR PI0409916 A BRPI0409916 A BR PI0409916A
Authority
BR
Brazil
Prior art keywords
compounds
carboxylic acids
phenyl substituted
ptp
substituted carboxylic
Prior art date
Application number
BRPI0409916-8A
Other languages
English (en)
Inventor
Darren Whitehouse
Shaojing Hu
Haiquan Fang
Michael C Van Zandt
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of BRPI0409916A publication Critical patent/BRPI0409916A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

"áCIDOS CARBOXìLICOS SUBSTITUìDOS COM FENILA". São revelados compostos e sais farmaceuticamente aceitáveis de fórmula (A): os quais são úteis no tratamento de distúrbios metabólicos relacionados com resistência à insulina, resistência à leptina, ou hiperglicemia. Compostos da invenção incluem inibidores de Proteína tirosina fosfatases, em particular Proteína tirosina fosfatase-1B (PTP-1B), que são úteis no tratamento de diabetes e outras doenças mediadas pela PTP, tais como câncer, doenças neurodegenerativas e semelhantes. Também são reveladas composições farmacêuticas compreendendo compostos da invenção e métodos para tratar as condições mencionadas acima usando os compostos referidos.
BRPI0409916-8A 2003-04-30 2004-04-30 ácidos carboxìlicos substituìdos com fenila BRPI0409916A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46686803P 2003-04-30 2003-04-30
PCT/US2004/013701 WO2004099170A2 (en) 2003-04-30 2004-04-30 Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b

Publications (1)

Publication Number Publication Date
BRPI0409916A true BRPI0409916A (pt) 2006-04-25

Family

ID=33434989

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409916-8A BRPI0409916A (pt) 2003-04-30 2004-04-30 ácidos carboxìlicos substituìdos com fenila

Country Status (13)

Country Link
US (1) US7524878B2 (pt)
EP (1) EP1620422A2 (pt)
JP (1) JP2006525365A (pt)
KR (1) KR20060006954A (pt)
CN (1) CN1812978A (pt)
AU (1) AU2004236248A1 (pt)
BR (1) BRPI0409916A (pt)
CA (1) CA2524235A1 (pt)
EA (1) EA200501713A1 (pt)
MX (1) MXPA05011536A (pt)
NO (1) NO20055129L (pt)
WO (1) WO2004099170A2 (pt)
ZA (1) ZA200509635B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525364A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換アミノカルボン酸
KR20060080197A (ko) 2003-09-17 2006-07-07 오노 야꾸힝 고교 가부시키가이샤 카르복실산 화합물 및 이들을 유효 성분으로서 함유하는의약 조성물
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
EP1844043A2 (en) * 2004-11-18 2007-10-17 The Institutes for Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids for the treatment of diabetes
EP1836182A2 (en) * 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
JP2008520693A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー プロテインチロシンホスファターゼ阻害剤としての置換アミノ酸
DE102004060542A1 (de) * 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung
WO2006117657A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN101296914B (zh) 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
WO2008033934A1 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryl carboxylic acid derivatives as ptb-1b inhibitors
WO2008033931A1 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011506445A (ja) * 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ES2512727T3 (es) 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
JP5814031B2 (ja) * 2010-07-30 2015-11-17 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、及びジベンゾチオフェン構造又はジベンゾフラン構造を有する有機電界発光素子用材料
CN102382037B (zh) * 2010-09-03 2016-01-20 中国医学科学院药物研究所 苯丙酸类化合物及其制法和药物用途
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
JP5989660B2 (ja) 2010-12-07 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換１−ベンジルシクロアルキルカルボン酸およびその使用
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
PT3013796T (pt) * 2013-06-27 2020-03-26 Lg Chemical Ltd Derivados biarílicos como agonistas de gpr120
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
CU24413B1 (es) 2014-12-18 2019-05-03 Bayer Pharma AG Ácidos piridil-cicloalquil-carboxílicos sustituidos útiles para el tratamiento de enfermedades asociadas al dolor, y para el tratamiento o profilaxis de los síndromes del dolor, de la endometriosis, la adenomiosis y el cáncer
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN116693514A (zh) * 2022-03-01 2023-09-05 上海璎黎药业有限公司 一类芳香环取代的甲氧基衍生物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243678A (en) * 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
JPS59141540A (ja) * 1983-02-01 1984-08-14 Chisso Corp 三環カルボン酸エステル誘導体
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
DE69821294T2 (de) * 1997-07-25 2004-11-18 Eastman Kodak Co. Lichtempfindliche Silberhalogenidemulsionsschicht mit verstärkter photographischer Empfindlichkeit
DE19907904A1 (de) * 1999-02-24 2000-08-31 Clariant Gmbh Verfahren zur Herstellung von [1,1':4',1"]-Terphenylverbindungen
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
AU2001239550A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
JP4105446B2 (ja) * 2002-02-20 2008-06-25 富士フイルム株式会社 重合性化合物およびそのマトリックスを用いた光学素子

Also Published As

Publication number Publication date
WO2004099170A3 (en) 2005-09-15
US7524878B2 (en) 2009-04-28
EA200501713A1 (ru) 2006-06-30
ZA200509635B (en) 2007-04-25
KR20060006954A (ko) 2006-01-20
WO2004099170A2 (en) 2004-11-18
US20050004369A1 (en) 2005-01-06
NO20055129L (no) 2006-01-23
MXPA05011536A (es) 2006-01-23
JP2006525365A (ja) 2006-11-09
CN1812978A (zh) 2006-08-02
AU2004236248A1 (en) 2004-11-18
EP1620422A2 (en) 2006-02-01
CA2524235A1 (en) 2004-11-18
NO20055129D0 (no) 2005-11-02

Similar Documents

Publication Publication Date Title
BRPI0409924A (pt) ácidos amino carboxìlicos substituìdos
BRPI0409447A (pt) ácidos fenilalcanóicos substituìdos
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
MXPA05011536A (es) Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
MXPA05011539A (es) Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
BRPI0409914A (pt) ácidos carboxìlicos substituìdos
WO2008033455A3 (en) Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
TW200630327A (en) Substituted phenylalkanoic acids
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
WO2006055625A3 (en) Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
BRPI0416796A (pt) compostos orgánicos
IL199914B (en) Use of protein kinase n beta for the manufacture of a diagnostic agent
BRPI0409109A (pt) novos compostos
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
TW200630354A (en) Substituted amino carboxylic acids
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
HRP20050103B1 (hr) N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.